The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients

被引:124
|
作者
Flechner, SM [1 ]
Zhou, LM [1 ]
Derweesh, I [1 ]
Mastroianni, B [1 ]
Savas, K [1 ]
Goldfarb, D [1 ]
Modlin, CS [1 ]
Krishnamurthi, V [1 ]
Novick, A [1 ]
机构
[1] Cleveland Clin Fdn, Transplant Ctr, Glickman Urol Inst, Sect Renal Transplantat, Cleveland, OH 44195 USA
关键词
D O I
10.1097/01.TP.0000093502.26208.42
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The aim of this study was to determine whether there has been an increase in the incidence or severity of wound-healing complications that can be attributed to the introduction of newer immunosuppressive drugs. Methods. Consecutive series of adult kidney-only transplant recipients were selected from our Unified Transplant Database backward from September 2002. There were 513 patients divided into groups on the basis of their maintenance immunosuppression given for at least the first 30 days posttransplant. Group I (152) was given sirolimus, mycophenolate mofetil, and prednisone (SRL/XMF/P) between March 2000 and September 2002; group II (168) was given cyclosporine A (CsA)/MMF/P between January 1999 and July 2002; and group III (193) was given azathioprine (AzA)/CsA/P between January 1993 and December 1997. A classification system for wound-healing problems was developed, and each of the three groups was analyzed by univariate and multivariate analysis. Results. From groups III to II to 1, there was a significant increase in mean age (42.4 vs. 49 years), percent of patients diabetic (17% vs. 29%), mean body mass index (BMI) (24.2 vs. 27.1 kg/m(2)), and percent BMI greater than 30 (13.5% vs. 27%). The cumulative percentage of all wound-healing problems between group I (19.7%) vs. group II (16.1%) and group III (15.6%) was not significantly different. The most significant risk factor was a recipient BMI greater than 30 (P=0.0012) and delayed graft function (P=0.0041). Conclusions. During a 10-year period marked by changing recipient demographics, the introduction of MMF and SRL did not result in a significant increase in transplant wound-healing complications. The most significant risk factor associated with transplant wound-healing complications remains body weight, which was the major influence for each of the immunosuppressive drug combinations described.
引用
收藏
页码:1729 / 1734
页数:6
相关论文
共 50 条
  • [41] Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil
    Herrero, JI
    Quiroga, J
    Sangro, B
    Girala, M
    Gomez-Manero, N
    Pardo, F
    Alvarez-Cienfuegos, J
    Prieto, J
    [J]. LIVER TRANSPLANTATION AND SURGERY, 1999, 5 (05): : 414 - 420
  • [42] CYCLOSPORINE VERSUS AZATHIOPRINE IN HIGH-RISK CADAVER KIDNEY-TRANSPLANT RECIPIENTS - A PROSPECTIVE RANDOMIZED STUDY
    NORMAN, DJ
    WETZSTEON, P
    BARRY, JM
    BENNETT, WM
    [J]. TRANSPLANTATION PROCEEDINGS, 1987, 19 (01) : 1845 - 1845
  • [43] The impact of conversion from mycophenolate mofetil to mycophenolate sodium among renal transplant recipients on a sirolimus-based regimen
    Kahan, B. D.
    Podbielski, J.
    Childs, B.
    [J]. TRANSPLANTATION PROCEEDINGS, 2008, 40 (05) : 1429 - 1434
  • [44] WITHDRAWAL OF AZATHIOPRINE AND ANTILYMPHOCYTE GLOBULINS IN KIDNEY-TRANSPLANT RECIPIENTS WITH CYTOMEGALOVIRUS
    MOURAD, G
    CHONG, G
    POULIQUEN, M
    RUIZ, G
    MANDIN, J
    MION, C
    [J]. TRANSPLANTATION PROCEEDINGS, 1984, 16 (05) : 1313 - 1315
  • [45] Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients
    Augustine, JJ
    Knauss, TC
    Schulak, JA
    Bodziak, KA
    Siegel, C
    Hirick, DE
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (12) : 2001 - 2006
  • [46] Mycophenolate Mofetil and the Incidence of Skin Cancer in Kidney Transplant Recipients
    Yusuf, S. J.
    Bheemreddy, H.
    Imtiaz, A.
    Krishnan, N.
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 831 - 831
  • [47] Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients?
    Johnson, DW
    Nicol, DL
    Purdie, DM
    Preston, JM
    Brown, AM
    Hawley, CM
    Campbell, SB
    Wall, D
    Griffin, AD
    Isbel, NM
    [J]. TRANSPLANTATION, 2002, 73 (07) : 1158 - 1163
  • [48] Clinical Significance of Mycophenolate Mofetil Withdrawal in Kidney Transplant Recipients
    Park, Woo Yeong
    Paek, Jin Hyuk
    Jin, Kyubok
    Park, Sung Bae
    Han, Seungyeup
    [J]. TRANSPLANTATION PROCEEDINGS, 2019, 51 (08) : 2633 - 2636
  • [49] Mycophenolate Mofetil Dose Adjustment in Pediatric Kidney Transplant Recipients
    Labriffe, Marc
    Micallef, Ludovic
    Woillard, Jean-Baptiste
    Monchaud, Caroline
    Saint-Marcoux, Franck
    Debord, Jean
    Marquet, Pierre
    [J]. THERAPEUTIC DRUG MONITORING, 2023, 45 (05) : 591 - 598
  • [50] Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients
    Ghio, L
    Ferraresso, M
    Viganó, SM
    Ginevri, F
    Perfumo, F
    Gianoglio, B
    Murer, L
    Zacchello, G
    Dello Strologo, L
    Cardillo, M
    Tirelli, S
    Valente, U
    Edefonti, A
    [J]. TRANSPLANTATION PROCEEDINGS, 2005, 37 (02) : 856 - 858